AVANT GARDE-TIMI 43

AVANT GARDE-TIMI 43 was a proof of concept trial to evaluate the efficacy of early RAAS inhibition with aliskiren (a renin antagonist), valsartan, or their combination in lowering natriuretic peptides in patients with acute coronary syndromes.

DOWNLOAD SLIDE SET (PDF)

Key Study Publications

Scirica, B. M., Morrow, D. A., Bode, C., Ruzyllo, W., Ruda, M., Oude Ophuis, A. J., Lopez-Sendon, J., Swedberg, K., Ogorek, M., Rifai, N., Lukashevich, V., Maboudian, M., Cannon, C. P., McCabe, C. H., Braunwald, E. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial European heart journal. 2010;31(16):1993-2005. Abstract